Graphite Bio stockholders approve 1:7 reverse split, name change to LENZ; effective March 21, trading as LENZ March 22

LENZ Therapeutics, Inc.

Stockholders approved 1-for-7 reverse stock split and name change to 'LENZ Therapeutics, Inc.' at March 14 special meeting.
Reverse split and name change effective 4:01 p.m. ET March 21, 2024; no fractional shares, cash paid in lieu.
Common stock trades on split-adjusted basis under ticker 'LENZ' from March 22, 2024; new CUSIP 52635N103.
Proportional adjustments made to outstanding equity awards and shares reserved under stock plans.
Actions taken in connection with pending merger with LENZ Therapeutics; merger closing expected thereafter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.